Transplantation
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or…
Date: 26th April 2024
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory…
Date: 15th March 2024
Updates, challenges and novel agents being explored in BPDCN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain…
Date: 25th January 2024
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic…
Date: 18th January 2024
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in…
Date: 24th November 2023
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years,…
Date: 10th November 2023
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…
Date: 3rd November 2023
iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 20th October 2023
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are…
Date: 6th October 2023
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 22nd September 2023
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of…
Date: 8th September 2023
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent…
Date: 23rd August 2023
